A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in
participants with cervical squamous intraepithelial lesions. This study is divided into 2
parts - Part A and Part B.
Part A consists of 3 dose escalating cohorts. Part B is a dose expansion cohort.
Participants will self-administer ABI-2280.